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Abstract: The Flex-Het compound 10a (SHetA2-NSC 721689) {[4-nitrophenylamino][(2,2,4,4-tetramethylthiochroman-
6-yl)amino]methane-1-thione]} has shown promise in preclinical testing as an anti-cancer agent without evidence of tox-
icity, skin irritancy, or teratogenicity. One objective of this study was to synthesize a series of heteroarotinoids structurally 
related to SHetA2 and to measure the effect of structural alterations on the cytotoxicity activities of the compounds on 
A2780 ovarian cancer cells. Alterations included comparisons of activity of an NO2 end group versus a CO2Et end group, 
a thiourea linker versus a urea linker, and a distorted, thiochroman ring unit versus a planar quinoline ring unit. Cytotoxic-
ity assays demonstrated the thiourea linker compounds to be similar in potency to the urea linker counterparts, the NO2 
substitutions were slightly more potent than the CO2Et substitutions, and replacement of the thiochroman group with a 
planar quinoline fused ring system markedly reduced activity. The mechanism of cytotoxicity through apoptosis was con-
firmed for the compounds. The optimal combination of structural features for enhancing potency consisted of a urea 
linker, a NO2 substitution, and a flexible thiochroman unit. Extensive H-bonding in the more active urea derivative was 
confirmed by X-ray and NMR analyses. This is the first example in which the biological activity of flexible, thiochroman 
units is compared to that of fused aryl units in a heteroarotinoid molecule. 
INTRODUCTION 
  Retinoid biology and chemistry remains an active area in 
cancer chemotherapy with certain synthetic systems exhibit-
ing reduced toxicity compared to natural retinoids [1-5]. 
Heteroarotinoids are a family of heterocycles which have 
demonstrated such reduced toxicity [6-7]. To illustrate, en-
dogenous  trans-retinoic acid (1) has a maximum tolerated 
dose (MTD) of 10 mg/kg/day in mice which is comparable 
to a dose of 9.4 mg/kg/day for 2 (X = O, R = H). In contrast, 
acids  3 possessed MTD values of 32 mg/kg/day and 34 
mg/kg/day for X = O and X = S, respectively [7]. Since natu-
ral retinoids act with nuclear receptors to mediate biological 
activities by binding to specific DNA sequences [8-10], two 
members of 2 were examined and were selective for retinoic 
acid receptors (RARs) [7]. Recent studies have suggested 
that transcriptional activation of RAR by some retinoids 
may correlate with toxicity [11-12]. Thus, RAR activation by 
synthetic retinoids may have limitations in terms of useful 
chemotherapy, although more study is needed. Two mem-
bers of 3 (X = O, S) were good inducers of differentiation in 
human HL-60 cells (promyelocytic cells) with ED50 values at 
the nanomolar level and similar to that of 1 and better than 
the two members of 2 (X = O, R = H and Et) which had ED50 
values in the micromolar range [13]. Thus, biological activ-
ity with such systems is sensitive to small structural changes. 
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  Increasing the length and nature of the linker between the 
two aryl rings in 2 resulted in the generation of selected ex-
amples of 4. The urea and thiourea linkers in 4 added a 
flexible property to the molecules which was reasoned ini-
tially to be better accommodated in the RAR receptor [14-
19]. In three examples of 4 examined to date [16], the agents, 
termed Flexible Heteroarotinoids (Flex-Hets) were receptor 
independent/apoptotic as diagnosed via  the treatment of 
ovarian primary and cancerous cell lines OVCAR-3, Caov-3, 
and SK-OV-3. Later work revealed that the compounds in-
hibited multiple types of malignant cell lines and similar 
ovarian malignant cell lines with only very weak activity 
against normal and benign cells [17-19]. Growth inhibition 
was correlated with apoptosis and the generation of reactive 
oxygen species. Synthetic retinoids as inducers of apoptosis 
in a variety of carcinoma cells have been demonstrated, for 
example, with 6-[3-(1-adamantyl)]-4-hydroxylphenyl-2-
naphthalenecarboxylic acid (5) without receptor activation 
[20-24]. Evidence for the molecular pathways for induce-
ment of apoptosis in ovarian cancer cells by 5 and 4-HPR (6) 
was recently made available [20-23]. One facet of the 
mechanism of action was the depolarization of the mito-
chondrial membrane. The mechanism by which 4 induces 
apoptosis in cancer cells over normal cells however, has 
been shown to occur through direct effects on the mitochon-
dria and Bcl-2 family of proteins [25]. Apoptosis is currently 
recognized as an avenue for cancer chemotherapy [21]. The 
current common line of treatment for ovarian cancer is the 
use of cisplatin (Platinol) or carboplatin (Paraplatin). How-
ever, resistance to cisplatin has become a major issue [26]. 
  In an effort to further elucidate structural-activity rela-
tionships with systems containing the urea/thiourea linkers 
related to 4, a series of heteroarotinoids was prepared with a 12    The Open Medicinal Chemistry Journal, 2007, Volume 1  Le et al. 
large hydrophobic group as the fused-aryl ring unit and ex-
amined for ability to inhibit growth of A2780 ovarian cancer 
cells. In view of the biological response to conformationally 
restricted retinoids, such as TTNPB (7) which is toxic, how-
ever, and the clinical utility of Tazarotene (8), systems 9 
were prepared with a nitrogen atom in a planar quinoline 
unit. For the sake of comparison of activities, members of 10 
possessing a sulfur atom in a flexible, thiochroman ring unit 
were evaluated. A search of the literature did not reveal any 
heteroarotinoids with diheteroaryl-substituted, flexible link-
ing urea or thiourea groups structurally similar to 9. Diaryl-
substituted retinoids with rigid linkers or void of linking 
groups between the rings are known, such as with 6-[3’-(1-
adamantyl)-4’-hydroxyphenyl]-2-naphthalenecarboxylic acid 
(5), which possess ability to inhibit growth of cancerous cells 
and to induce apoptosis independent of receptor activation 
[24]. The recent example of a similar structure 11 [IC50 = 
1.76 μM] possessed strong inhibitory ability against chloro-
quine-resistant strain of Plasmodium falciparum, the human 
malaria parasite. No specific mechanism of action was re-
ported [27-29]. It is also noteworthy that the related het-
eroarotinoid  12 displayed moderate activity against the 
growth of Mycobacterium bovis BCG [30]. 
H H
H H
O
NN
O
OCH3
OCH3
OCH3 11
S
NN
O 12
O
OC2H5
 
MATERIALS AND METHODOLOGY 
General Chemistry Information 
 Compounds  10a, 10b, and 10d were prepared from lit-
erature procedures [17-19]. 
  In a typical experiment, the equipment used was a 25-
mL, three-necked, round-bottomed flask equipped with a N2 
inlet, a condenser, a magnetic stirrer and an addition funnel. 
Glassware was oven-dried prior to use and flushed with N2 
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10 a.  X = S;   Z = NO2
     b.  X = S;   Z = CO2Et
     c.  X = O;   Z = NO2
     d.  X = O;   Z = CO2Et
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when assembled. All isocyanates and isothiocyanates were 
obtained from Aldrich Chemical Company, Milwaukee, WI. 
Commercial solvents were used as received except all were 
dried over molecular sieves 3a prior to use. Extended periods 
of drying over molecular sieve 3a were required with THF to 
minimize the water content and maximize the yields of 
products from the condensation of the isocyanates (isothio-
cyanates) with the appropriate amines. Melting points of 
products were taken on a Thomas-Hoover capillary unit and 
were uncorrected. IR spectra were recorded on a Perkin-
Elmer 2000 FT-IR as liquid films or as KBr pellets. The 
NMR spectra were taken on a Varian Unity Gemini 300 
MHz unit operating at 300.082 MHz [
1H] and at 75.463 
MHz [
13C]. Some spectra were taken on a Varian Unity 
INOVA 400 MHz unit operating at 399.99 MHz [
1H] and at 
100.01 MHz [
13C]. Most samples were dissolved in DCCl3, 
unless otherwise specified, and signals were referenced to 
TMS [ for 
1H; ppm for 
13C] at RT. The 
15N NMR experi-
ments [tuned to 60.65 MHz] were conducted in DMSO-d6 on 
a Varian Unity INOVA 600 MHz unit. Chemical shifts for 
15N in samples were referenced to H4
15N-
15NO2 [
15N 95% 
doubly enriched + 85% D2O + 5% H2O + 10% HNO3] and 
then to liquid ammonia. TLC analysis employed Polygram 
Polyester sheets (0.2 mm thick) and were UV sensitive 
[UV254]. A Waters Corporation semi-preparative HPLC unit 
[model 2487, dual  detector, Sunfire prep silica column] 
was employed to determine purity of all samples in H2CCl2. 
Elemental analyses were performed by Atlantic Microlab, 
Inc., Norcross, GA 30091. 6-Amino-2-methylquinoline (13, 
97%, mp 189-191°C) was purchased from Alfa Aesar Com-
pany, Ward Hill, MA 01835-6904, and was used directly. 
General Chemistry Procedures 
  As a general procedure, the mixture was cooled to 0°C 
(ice bath), and 4-nitrophenyl isocyanate (1.04 eq) (or 4-
nitrophenyl isothiocyanate or other substituted derivatives) 
in dry THF (5 mL) was added dropwise (~5 min) to a solu-
tion of the required amine (1.00 eq) in dry THF (3 mL). Af-
ter the addition, the reaction mixture was allowed to warm to 
RT and was then stirred (magnetic) for 24 h. During the 24 h 
period of stirring, additional THF was added to maintain 
volume. The solvent was removed in vacuo to give a heavy 
oil, which was crystallized, or a solid which was recrystal-
lized from a suitable solvent or was dissolved in an appropri-
ate solvent (see individual experiments for the solvent used) 
and subjected to flash chromatography [Baker silica gel, 40 
μm particle size] to give a pure product. 
 1-(2-Methylquinolin-6-yl)-3-(4-nitrophenyl) thiourea 
(9a). Commercial 6-amino-2-methylquinoline (13, 158 mg, 
1.0 mmol) dissolved in dry THF (6 mL) was cooled to 0°C 
(ice bath), and 4-nitrophenyl isothiocyanate (184 mg, 1.02 
mmol) in dry THF (5 mL) was then added dropwise. After 
the addition, the reaction mixture was allowed to warm to 
RT and was then stirred for 24 h. The THF was then re-
moved in vacuo to give a dark yellow solid. The solid was 
subjected to flash chromatography [EtOAc:hexanes,(1:2)] on 
silica gel and gave 9a (268 mg, 79.2%) as a bright yellow 
solid: mp 113-115°C; IR (KBr) 3285 [NH], 3172 [NH] cm
-1; 
1H NMR (DMSO-d6)  2.63 (s, 3 H), 7.38 (d, 1 H, J = 8.6 
Hz), 7.78 (d, 2 H, J = 9.2), 7.87 (m, 3 H, J = 8.6 Hz), 8.03 (s, 
1 H) 8.22 (d, 2 H, J = 9.2), 9.75 (s, 1 H, NH), 10.24 (s, 1 H, 
NH); 
13C NMR (DMSO-d6) ppm 24.7 [CH3], 120.3-158.1 
[Ar-C], 179.5 [C=O]. Anal. (C17H14N4O2S) C, H, N, S: C, 
60.34; H, 4.17; N, 16.56, S, 9.48. Found: C, 60.12; H, 4.20; 
N, 16.39; S, 9.44. 
 1-(2-Methylquinolin-6-yl)-3-(4-nitrophenyl)urea (9b). 
6-Amino-2-methylquinoline (13, 158 mg, 1.0 mmol) dis-
solved in dry THF (6 mL) was cooled to 0°C (ice bath), and 
4-nitrophenyl isocyanate (167 mg, 1.02 mmol) in dry THF (5 
mL) was then added dropwise. The remaining procedure was 
the same as for 13a and yielded a brownish yellow solid. The 
solid was subjected to flash chromatography [i-propanol: 
hexanes (1:1)] on silica gel and gave 9b (201 mg, 62.3%) as 
a bright yellow solid: mp 241-242°C; IR (KBr) 3330 [NH], 
3295 [NH] cm
-1; 
1H NMR (DMSO-d6)  2.60 (s, 3 H), 7.34 
(d, 2 H, J = 8.6 Hz), 7.63 (m, 1 H), 7.71 (d, 1 H, J = 6.7 Hz), 
7.85 (d, 2 H, J = 8.6 Hz), 8.14 (m, 1 H), 8.19 (d, 2 H, J = 6.7 
Hz), 9.19 (s, 1 H, NH), 9.52 (s, 2 H, NH); 
13C NMR 
(DMSO-d6) ppm 24.7 [CH3], 120.3-158.1 [Ar-C], 179.5 
[C=O]. Anal. (C17H14N4O3S) C, H, N, S. C, 63.35; H, 4.38; 
N, 17.38. Found: C, 63.07; H, 4.44; N, 17.32. 
  Ethyl 4-[3-(2-Methylquinolin-6-yl)ureido]benzoate (9c). 
6-Amino-2-methylquinoline (13, 158 mg, 1.0 mmol) dis-
solved in dry THF (6 mL) was cooled to 0°C (ice bath), and 
4-ethoxycarbonylphenyl isocyanate (195 mg, 1.02 mmol) in 
dry THF (5 mL) was then added dropwise. The remaining 
procedure was as for 9a and led to a yellow solid. Recrystal-
lization (methanol) gave 9c (290 mg, 69.5%) as white nee-
dles: mp 232-233°C; IR (KBr) 3320 [NH], 3301 [NH], 1709 
[C=O] cm
-1; 
1H NMR (DMSO-d6)  1.32 (t, 3 H, J = 4.3 
Hz), 2.62 (s, 3 H), 4.29 (q, 2 H, J = 4.3 Hz, CH2), 7.35 (d, 2 
H, J = 9.2 Hz, Ar-H), 7.64 (d, 1 H, J = 8.3 Hz, Ar-H), 7.67 
(d, 1 H, J = 8.3 Hz, Ar-H), 7.87 (d, 1 H, J = 6.3 Hz, Ar-H), 
7.92 (d, 2 H, J = 9.2 Hz, Ar-H), 8.15 (d, 1 H, J = 6.3 Hz, Ar-
H), 8.17 (s, 1 H, Ar-H); 9.08 (s, 1 H, NH), 9.21 (s, 1 H, NH); 
13C NMR (DMSO-d6) ppm 14.2 [CH3], 24.6 [CH3, 
OCH2CH3], 60.2 [CH2, OCH2CH3], 113.5-156.6 [Ar-C], 
165.4 [C=O]. Anal. (C20H19NO3) C, H, N, S: C, 68.75; H, 
5.48; N, 12.03. Found: C, 68.54; H, 5.50; N, 11.91. 
 1-(2,2,4,4-Tetramethylthiochroman-6-yl)-3-(4-nitrophe-
nyl)urea (10c). Amine 14 (221 mg, 1.0 mmol) dissolved in 
dry THF (6 mL) was cooled to 0°C under N2. 4-Nitrophenyl 
isocyanate (167 mg, 1.02 mmol) in dry THF (5 mL) was 
added dropwise. The remaining procedure was as for 9a and 
gave a brown solid which was subjected to flash chromatogra-
phy [EtOAc:hexanes, (1:2)] on silica gel. Evaporation of the 
solvent gave 10c (257 mg, 72%) as a bright yellow solid: mp 
173-174°C; IR (KBr) 3219 [NH], 3189 [NH] cm
-1; 
1H NMR 
(DMSO-d6)  1.33 [s, 6 H, C(CH3)2], 1.35 [s, 6 H, SC(CH3)2], 
1.90 [s, 2 H, CH2], 6.98 [d, 1 H, J = 8.2 Hz, Ar-H], 7.18 [dd, 1 
H, J = 8.2, 2.2 Hz, Ar-H], 7.59 [d, 1 H, J = 2.2 Hz, Ar-H], 7.67 
[d, 2 H, J = 9.0 Hz, Ar-H], 8.16 [d, 2 H, J = 9.0 Hz, Ar-H], 
8.83 [s 1 H, NH], 9.38 [s, 1 H, NH]; 
13C NMR (DMSO-d6) 
ppm 31.2 [C(CH3)2], 32.1 [SC(CH3)2], 35.3 [C(CH3)2], 41.8 
[SC(CH3)2], 53.6 [CH2], 117.2-146.4 [Ar-C], 151.90 [C=O]. 
Anal. (C20H23N3O3S) C, H, N, S: calcd, C, 62.32; H, 6.01; N, 
10.90; S, 8.32. Found: C, 62.42; H, 6.10; N, 10.74; S, 8.31. 
Experimental Section for X-Ray Analysis 
  The X-ray intensity data were measured on a Bruker 
SMART APEX II CCD area detector system equipped with 
a graphite monochromator and a Mo K fine-focus sealed 
tube ( = 0.71073 Å) operated at 1.5 kW power (50 kV, 30 14    The Open Medicinal Chemistry Journal, 2007, Volume 1  Le et al. 
mA). The detector was placed at a distance of 6.00 cm from 
the crystal. The total data collection time was 24 hours for 
each compound. The frames were integrated with the Bruker 
SAINT Software [31] package using a narrow-frame integra-
tion algorithm. Analysis of the data showed negligible decay 
during data collection. Data were corrected for absorption 
effects using the multiscan technique (SADABS) [32]. The 
structure was solved and refined using the SHELXTL [33] 
software package. The X-ray structures are in Figs. (1,2) 
with hydrogen atoms displayed with an arbitrarily radius. 
 
 
Fig. (1). A view of 10a and 10a rotated 90° in the Z direction with the numbering scheme employed. 
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  A clear, light yellow block (0.44 x 0.48 x 0.98 mm) of 
10a was used for the X-ray crystallographic analysis. A total 
of 2522 frames were collected with a scan width of 0.5° in  
and  with an exposure time of 30 sec/frame. The integra-
tion of the data using a monoclinic cell was to 0.80 Å resolu-
tion [redundancy 8.2, completeness = 99.6%, Rint = 3.77%, 
Rsig = 2.14%]. The final cell constants are based upon the 
refinement of the XYZ-centroids of 6502 reflections above 
2 (I) with 4.68° < 2 < 52.74°. The ratio of minimum to 
maximum apparent transmission was 0.8098. Additional 
statistics for the X-ray structure determination of 10a are 
listed in Table 1. 
  A clear, yellow wedge (0.10 x 0.33 x 0.44 mm) of 10c 
was used for the X-ray crystallographic analysis. A total of 
2519 frames were collected with a scan width of 0.5° in  
and  and an exposure time of 30 sec/frame. The integration 
of the data using an orthorhombic cell was to 0.80 Å resolu-
tion [redundancy 11.3, completeness = 100.0%, Rint = 
4.06%, Rsig = 1.90%]. The final cell constants are based upon 
Table 1.  Crystal and Refinement Data for 10a and 10c 
 
 10a  10c 
Formula  C20H23N3O2S2 C 20H23N3O3S 
FW  401.53 385.47 
Crystal system  monoclinic orthorhombic 
Space group  P21/c Pbca 
Crystal size  0.44x0.48x0.98 mm  0.104x0.329x0.441 mm 
Crystal color  clear yellow block  clear yellow wedge 
a = 17.4651(18)Å  = 90°  a = 9.4300(19)Å  = 90° 
b = 7.1952(8)Å  = 94.450(7)°  b = 12.980(3)Å  = 90°  Cell dimensions 
c = 16.2792(17)Å  = 90°  c = 32.020(6)Å  = 90° 
Volume  2039.6(4) Å
3 3919.3(14)  Å
3 
Density (calcd) g/cm
3  1.308 1.307 
Z  4 8 
Absorption coefficient  0.281 mm
-1 0.190  mm
-1 
Temperature (K)  298(2) 293(2) 
Radiation  μ(MoK)  μ(MoK) 
33882 measured  45226 measured 
4141 independent  3998 independent  Reflections 
3283 [(with I>2(I)]-observed  3306 [(with I>2(I)]-observed 
Diffractometer  Bruker APEX II CCD  Bruker APEX II CCD 
max  26.37° ( = 2.34-26.37°)  26.37° ( = 2.51-26.37°) 
Refinement on F
2  wR(F
2) = 0.1947  wR(F
2) = 0.0815 
1/[
2(F
2) + (0.0950P)
2 + 1.8519P]  1/[
2(F
2) + (0.0605P)
2 + 1.6077P] 
w 
[P = (F
2 + 2Fc
2)/3]  [P = (F
2 + 2Fc
2)/3] 
R[F
2>2(F
2)]  0.0633 0.0459 
Parameters  249 249 
(/)max  0.580 0.135 
S  1.037 1.027 
()max  0.844 e/Å
3 0.500  e/Å
3 
()min  -0.409 e/Å
3 -0.368  e/Å
3 
F(000)  848 1632 16    The Open Medicinal Chemistry Journal, 2007, Volume 1  Le et al. 
the refinement of the XYZ-centroids of 3306 reflections 
above 2 (I) with 5.02° < 2 < 52.74°. The ratio of mini-
mum to maximum apparent transmission was 0.8222. Other 
information on 10c is given in Table 1. 
Biology Methods-Cytotoxicity Assays and Tissue Culture 
  The CellTiter 96 AQueous One Solution Cell Proliferation 
Assay (Promega) was used to measure living cells remaining 
after 48 hours of incubation with or without a range of con-
centrations for the heteroarotinoids. MTS [3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) 
-2H-tetrazolium, inner salt], a novel tetrazolium compound, 
was added to each well and incubated for 4 hours, followed 
by addition of a solublization/stop solution. After overnight 
incubation, the optical density (OD) of each well was deter-
mined by measuring the absorbance at 540 nm using a 
Dynex MRX Revelation microtiter plate reader. Treatments 
were performed in triplicate, and the growth indices were 
derived by dividing the average OD540 of each treatment by 
the average OD540 of control cultures. The results represent 
the average and standard error of two to three independent 
experiments. 
 Apoptosis  Assay. Cells were plated in 6-well tissue cul-
ture dishes at a cell density of 1 x 10
5 cells/well. After allow-
ing cells to adhere to the dishes overnight, parallel cultures 
were treated with varying concentrations of heteroarotinoids 
or the same volume of DMSO solvent for 24 hours. The Vy-
brant™ Apoptosis Assay Kit #3 (Molecular Probes) was 
then utilized to measure apoptosis and necrosis. Tissue cul-
ture medium in each well was collected to harvest cells that 
had already lifted off the tissue culture plate. These were 
combined with adherent cells that were harvested by 
trypsinization. The cells were pelleted by centrifugation and 
resuspended in 100 μL of 1X annexin-binding buffer, and 
then they were incubated with 5 l of annexin V conjugated 
to fluorescein (Annexin-V-FITC) and 1 L of 100 g/mL 
propidium iodide (PI) for 15 minutes at room temperature. 
The solution was then mixed gently with an additional 400 
l of 1X annexin-binding buffer, and the samples were 
evaluated with a FACSCalibur (Becton Dickinson) auto-
mated benchtop flow cytometer at an excitation wavelength 
of 488 nm with observation wavelengths of 530 nm and 575 
nm. Flow cytometry data were quantified using Summit for 
MoFlo Acquisition and Sort Control Software (Cytomation, 
Inc). 
 Tissue  Culture. The A2780 ovarian cancer cells were 
cultured in RPMI media, and normal endometrial cells were 
cultured in MEM media. Both media contained fetal bovine 
serum (FBS), sodium pyruvate, and antibiotic/antimycotic. 
The normal endometrial cells were collected from a healthy 
premenopausal female and used prior to passage [34] as pre-
viously described. 
RESULTS AND DISCUSSION 
Chemistry 
  Key intermediates for the synthesis of members of 9 and 
10 were 6-amino-2-methylquinoline (13) and 2,2,4,4-
tetramethyl-6-aminothiochroman (14). Amine 13 is commer-
cial, although only in a purity of 98%, but was used directly 
without further purification. The thiochroman 14 was not 
commercial and was prepared [19]. The general methodol-
ogy is outlined below to obtain 9 and 10. A critical parame-
ter in the procedure required the use of exceptionally dry 
THF. Final yields of pure materials were obtained via flash 
chromatography or from one recrystallization of the reaction 
product from an appropriate solvent. Targets 9 and 10 had 
sharp melting points, exhibited spectral properties as ex-
pected for the structures, were soluble in DMSO (RT), and 
gave satisfactory elemental analyses. Members of 10 were 
also soluble in 95% ethanol and absolute ethanol. 
N CH3
NH2
S
NH2
13 14
 
Z NCX 13
14
9  a  79%
    b  62%
    c  67%
10  a  80%
      b  92%
      c   72%
      d  69%
dry THF/RT/24 h
 
Structural Analyses of 10a and 10c 
  The recognition of retinoid-type structures as potential 
anti-cancer agents for the clinic has received considerable 
attention [5]. These summaries included a variety of diaryl 
amides and a small number of N,N’-diaryl ureas. Recently, 
several N,N’-arylalkyl-substituted ureas exhibited other use-
ful biomedical properties [27-29]. In view of the activity 
found [16-17,19] for certain heteroarotinoids with a urea or 
thiourea linker between the aryl groups, it was deemed pru-
dent to determine crystal structures of 10a and 10c in addi-
tion to an examination of 
1H NMR structural data over a 
temperature range to ascertain if a certain conformer pre-
dominated. 
  The strong activity, the paucity of members of this family 
of heteroarotinoids, the need for insight as to the favored 
structure of such systems, and the likely strong H-bonding 
that could occur prompted an effort to grow crystals of 10a 
and 10c which were the most active. Compounds 10a and 
10c crystallized as a clear yellow block and a clear yellow 
wedge, respectively. The crystal and refinement data for both 
derivatives are presented in Table 1. Interestingly, 10a ex-
hibited a monoclinic system while 10c was orthorhombic. 
Supplementary information has selected bond distances and 
bond angles for both crystals. It is clear from the ORTEP 
drawings (Figs. 1,2) that in the solid state the ring units at-
tached to the two nitrogen atoms in each molecule are in an 
anti arrangement with respect to each other and in a syn ar-
rangement with respect to the sulfur atom (S2) in 10a and to 
the oxygen atom (O1) in 10c. The entire molecular frame-
work in 10a is nearly planar while in 10c the nitro-
containing aryl ring is essentially orthogonal to the thio-
chroman unit. One might expect a “stacking” of rings since 
the thiochroman unit is electron donating while the nitro-
substituted ring is electron withdrawing. Intramolecular ring 
stacking has been reported for N-anisyl-N’-(4-nitrophenyl) 
urea (15a) and N,N’-dimethyl-N,N’-di(4-nitrophenyl)urea Heteroarotinoids with Anti-Cancer Activity Against Ovarian Cancer Cells  The Open Medicinal Chemistry Journal, 2007, Volume 1    17 
(15b) via a charge transfer effect/reduced electron repulsive-
ness between phenyl rings, respectively [35-37]. Indeed, an 
earlier study revealed that N ,N’-diethyl-N,N’-diphenylurea 
crystallized (15c) in a syn arrangement in which the two 
phenyl rings were 3.90 Å apart from center to center. Sur-
prisingly, the center-to-center distance between phenyl rings 
in N,N’-dimethyl-N,N’-di(4-nitrophenyl)urea (15b) was even 
smaller (3.80 Å), presumably due to crowding induced by 
the two alkyl groups and/or, as suggested by the authors, 
reduced electron repulsion between the rings. The NCN 
bond angles were recorded for 15b and 15c as 117.8° and 
115.2°, respectively, while that for 15a was not reported. 
When a large nitro group was placed in an ortho position, the 
two aryl groups in 16 repositioned anti to each with a NCN 
bond angle of 115.4° and a distance of 2.11 Å from carbon-
to-carbon for the methyl groups [38]. 
  Ring-ring stacking has been postulated for a few ureas as 
indicated above, in addition to varying syn and anti arrange-
ments for N,N’-substituted aryl groups [35-40]. Both systems 
are somewhat flattened in certain regions (Fig. 1) and have 
the substituted aryl functions in a syn arrangement to the 
C=S and C=O bonds, respectively. The torsion angles de-
fined by C6-C5-C4a-C4 in the thiochroman units in 10a and 
10c are 176.4° and 175.18°, respectively. Thus the thiochro-
man system deviates slightly from planarity. A striking dif-
ference in the two molecules in the solid state is the orthogo-
nal position of the 4-nitrophenyl group in 10c with respect to 
the fused, thiochroman ring unit (Fig. 2). In contrast, the 
corresponding 4-nitrophenyl group in 10a is nearly planar 
with the fused ring counterpart. Moreover, 10a has a geminal 
dimethyl group almost facing the C=S bond while in 10c the 
geminal dimethyl groups are positioned remotely from the 
C=O bond, and the entire sulfur-containing portion of the 
fused ring system is turned away from the C=O group. The 
NCN’ bond angle was only slightly smaller [112.9°(2)] in 
10a than in 10c [113.81°(13)]. Interestingly, the correspond-
ing bond angles in thiourea and urea have been reported as 
116.0°(±1.0°) and 117.0°(±0.3°), respectively [41-44]. The 
shorter N2-C9 bond [1.343(4)Å] in 10a, compared to that in 
10c [1.354(2)Å], may reflect the repulsive nature of the 
fused ring with the long C=S bond [1.690(3)Å] versus the 
smaller, highly polarized C=O group [1.2264(19)Å] in 10c. 
Interestingly, the N-C bonds in thiourea versus urea have 
been recorded as 1.33(0.0l)Å and 1.351(0.007)Å, respec-
tively [41]. Surprising was the para-substituted phenyl ring 
in 10c positioned orthogonal to the fused ring system and 
away from the C=O bond, presumably to minimize interac-
tions of the latter with the ortho hydrogens of the phenyl 
ring. 
  Torsional angles C6-N1-C9-S2 and C6-N1-C9-O1 reflect 
the slight deviation from planarity of the fused ring with the 
linking group with values of +1.8(4)° and +6.6(3)°, respec-
tively, in 10a and 10c. Similarly, on the opposite side of the 
C=X bond both torsion angles S2-C9-N2-C10 and O1-C9-
N2-C10 possess nearly identical values of -9.5(4)° and   
-9.8(3)°, respectively, in 10a and 10c. In addition, the X-ray 
determination of single crystals of 10c demonstrated the ex-
istence of a unique lattice network involving hydrogen bond-
ing between hydrogens on N and an oxygen atom of the 
C=O group in a separate molecule in an intermolecular 
stacked alignment (Fig. 3) in an alternating “donor-acceptor” 
type of arrangement. This situation did not persist in 10a 
(Fig. 3), presumably due to a lack of adequate H-bonding 
between the hydrogens on N with the S atom in a separate 
molecule. A most interesting feature in the stacked units of 
10c was the alternating positions of the lone phenyl ring 
above the fused ring unit in individual molecules. The donor-
acceptor alignments between molecules must reflect an addi-
tional stabilizing property of the lattice in 10c. 
 Variable  temperature 
1H NMR studies (400 MHz) of 10a, 
10c,  and 10d were performed to determine if any major 
change in conformations occurred over a wide temperature 
range (Tables 2,3). For the higher temperature study 
(DMSO-d6) measurements from 22°C(RT)40°C80°C of 
the chemical shift differences in the two sharp signals for the 
two sets of geminal dimethyl groups revealed ranges from 
0.043 ppm to 0.031 ppm for 10a, 0.017 ppm to 0.010 ppm 
for 10c, and 0.018 ppm to 0.010 ppm for 10d. The implica-
tion is clear that very little change occurs in the conforma-
tion of the fused ring. The 10a, 10c, and 10d compounds 
precipitated in DMSO-d6 around 0°C. Therefore, the chemi-
cal shift differences for the same geminal dimethyl groups 
had to be observed at lower temperatures in DCCl3 or ace-
tone-d6 [22°C(RT)0°C-40°C-80°C] and ranged from 
0.048 ppm to 0.059 ppm and 0.046 to 0.081 ppm for 10a and 
10c, respectively. Solubility limitations prevented accurate 
measurements at -80°C in both cases. Similar chemical shift 
measurements involving ester 10d required acetone-d6 as the 
solvent over the same low temperature range and gave dif-
ferences in the geminal dimethyl signals from 0.010 ppm 
(80°C) to 0.020 ppm (-80°C). In all of these instances, the 
small differences reflect very little change in the conforma-
tions regarding the fused ring unit containing the partially 
saturated, flexible thiochroman ring. 
  An evaluation of the proton signals on the fused aryl 
group and on the separate aryl group in 10a, 10c, and 10d 
gave similar results over the temperature range of RT to 
80°C in DMSO-d6 and RT to –40°C in DCCl3 as described 
N N
O
R R
X Y
N
O
N
NO2
O2N
NO2 O2N
H3C CH3
115.4
degrees
16
15  a R = Me, X = MeO, Y = NO2
      b R = Me, X = Y = NO2
      c R = Et,   X = Y = H
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above. However, 10d required acetone-d6 as the solvent due 
to solubility limitations in DCCl3 for low temperature work. 
The 
3JHa-Hb values for 10a varied from 9.34 Hz (80°C) to 
8.24 Hz (-40°C), again indicating very little change in the 
conformation. Proton coupling of Ha-Hb in 10c varied only 
from 9.34 Hz (80°C) to 8.24 Hz (-40°C). In fact, the 
3J value 
was 8.24 Hz at RT as well as at –40°C for 10c in DCCl3. 
Ester 10d had 
3JHa-Hb values of 8.79 Hz (80°C) to 9.22 Hz  
(-80°C). Consequently, a reasonable conclusion is that the 
basic skeletal arrangement in these systems remains nearly 
constant in solution since all of the differences in 
3J cou-
plings were less than 1 Hz except for 10a which had a differ-
ence of 1.01 Hz from 80°C to –40°C. In view of the X-ray 
data, intramolecular H-bonding involving 10c is defensible 
from the NMR results. 
  In an overall assessment, one might expect, for example, 
considerable H-bonding involving the protons on nitrogen in 
the compounds with DMSO compared to a similar situation 
in acetone. This should lead to a breakup of any lattice type 
arrangement, especially in 10c and to some degree in 10a. 
The negligible changes in 
3JHa-Hb values for all three com-
pounds implies a type of solvation in both solvents which 
 
Fig. (3). Packing in the crystal structures of 10a (top) and 10c (bottom). Important distances for 10a are N1-S2 = 3.319Å and N2-S2 = 
3.370Å [with a molecule in another layer (not shown)] but the hydrogen on the two N atoms are not properly aligned to form good H-bonds 
to S. In contrast, the corresponding distances for 10c are N1-O2 = 3.208Å and N2-O2 = 2.833Å, and the hydrogens on the N atoms are 
aligned well with O and form good H-bonds. Heteroarotinoids with Anti-Cancer Activity Against Ovarian Cancer Cells  The Open Medicinal Chemistry Journal, 2007, Volume 1    19 
does not alter the conformation of the systems to any appre-
ciable extent from +80°C to –40°C. In addition, the chemical 
shifts for the two protons on the para-substituted phenyl ring 
were essentially unchanged for the three derivatives ( 7.71-
7.85 for Ha,  8.17-8.25 for Hb-10a;  7.66-7.32 for Ha,  
7.87-8.15 for Hb-10c;  7.56-7.81 for Ha,  7.87-8.25 for Hb-
10d) which lends credence to our hypothesis that single con-
formers are present. Moreover, no additional signal splitting 
was observed at low temperatures which is expected for a 
single conformer. 
H H
S
CH3(A) CH3(A)
CH3(B)
CH3(B)
X
NN
Z
Ha
Hb X = S, Z = NO2 (10a)
X = O, Z = NO2 (10c)
X = O, Z = CO2Et (10d)
 
 An 
15N NMR analysis of 10a and 10c revealed two sig-
nals in each example, namely at 136.78/140.96 ppm for 10a 
and 112.02/116.43 ppm for 10c in DMSO-d6 at room tem-
perature. Signals for the corresponding 
15N atom in the re-
spective nitro groups were visible at 372.53 ppm (10a) and 
372.35 ppm (10c). Model systems of substituted thioureas 
and ureas are rare in the literature [42-43]. Some simple sys-
tems with 
15N signals referenced from NH3 (liquid) are as 
follows: Ph-NO2 [
15N = 370.3 ppm], 4-O2N-C6H4-NH2 [
15N 
= 371.0 ppm (NO2) and 74.5 (NH2)], Ph-NH2 [
15N = 59.7 
ppm], Ph-NH-C(O)-NH-Ph [
15N = 108.8 ppm], H2N-C(O)-
NH2 [
15N = 77.59 ppm], and H2N-C(S)-NH2 [
15N = 110.9 
ppm]. The marked decreased shielding of 
15N in thiourea, 
compared to urea, does not offer an easy explanation since 
oxygen is more electronegative than sulfur. Tautomerism 
may exist with some thiourea derivatives which could influ-
ence the 
15N chemical shift [45-47]. 
Biological Results and Discussion 
  The abilities of the new heteroarotinoids to inhibit cancer 
growth were compared by growing the ovarian cancer cell 
line (A2780) in the absence and presence of various concen-
trations of the different compounds. The amount of cells 
remaining after 48 hours of treatment was measured using a 
cytotoxicity assay. The optical density (OD) endpoint of the 
assay represents the number of cells remaining after 48 hours 
Table 2.  The Chemical Shift Differences () for the Two Sets of Signals for H3C(A) and H3C(B) for 10a, 10c, and 10d Over the 
Temperature Range of 80°C to –80°C 
 
Compound   Value 
Temperature -80°C  -40°C  0°C  RT
  RT 40°C  80°C 
10a (DCCl3)  SL 0.059  0.052  0.048  0.043  0.040  0.031 
10c (DCCl3)  SL 0.081  0.058  0.046  0.017  0.015  0.010 
10d (Acetone-d6)  0.020 0.010  NT  0  0.018 0.015  0.010 
SL = solubility limitation; NT = not taken; DCCl3 freezes at –64°C. 
*Values were in DMSO-d6. 
 
Table 3.  Coupling Constants [
3JHa-Hb] in Hz and Chemical Shifts for Ha and Hb for 10a, 10c and 10d from 80°C to –80°C 
 
Compound 10a  10c  10d 
Temp (°C) 
3JHa-Hb (Hz)  chem. shift (ppm) 
3JHa-Hb (Hz)  chem. shift (ppm) 
3JHa-Hb (Hz)  chem. shift (ppm) 
Ha = 7.85  Ha = 7.66  Ha = 7.56 
80 9.34 
Hb = 8.17 
9.34 
Hb = 8.14 
8.79 
Hb = 7.87 
Ha = 7.82  Ha = 7.66  Ha = 7.56 
40 9.16 
Hb = 8.19 
9.34 
Hb = 8.14 
8.79 
Hb = 7.87 
Ha = 7.81  Ha = 7.66  Ha = 7.56 
RT 9.16 
Hb = 8.20 
9.34 
Hb = 8.15 
8.79 
Hb = 7.87 
 DCCl3 DCCl3 acetone-d6 
Ha = 7.75  Ha = 7.39  Ha = 7.78 
RT
  9.15 
Hb = 8.21 
8.24 
Hb = 7.94 
9.22 
Hb = 8.18 
Ha = 7.76  Ha = 7.36 
0 8.97 
Hb = 8.23 
8.24 
Hb = 7.92 
NT NT 
Ha = 7.71  Ha = 7.32  Ha = 7.70 
-40 8.24 
Hb = 8.25 
8.24 
Hb = 7.87 
9.22 
Hb = 8.22 
-80  SL  SL SL SL  9.22  Ha = 7.81 
Hb = 8.25 
Values from RT to 80°C were in DMSO-d6. The values at the lower temperatures [RT to –80°C] were in DCCl3 for 10a and 10c and in Acetone-d6 for 10d. [SL = solubility limita-
tion; DCCl3 freezes at –64°C; NT = not taken]. 20    The Open Medicinal Chemistry Journal, 2007, Volume 1  Le et al. 
of treatment. The Growth Index was derived by dividing the 
OD of treated cultures by the OD of untreated cultures. The 
results are presented in graphic form where Growth Index on 
the y axis represents the number of cells remaining after 48 
hours of treatment relative to untreated controls, and the x 
axis represents the concentration of drug added. The lower 
the Growth Index, the greater the growth inhibition. 
  Each of the sulfur-containing heteroarotinoids, 10a, 10b, 
10c, and 10d, inhibited the growth of ovarian cancer cultures 
in the micromolar range (Fig. 4). The potencies of the com-
pounds were derived by calculating the EC50 values, which 
are the concentrations that induce half maximal activity (Ta-
ble 4). Thus, the lower EC50 values represent more potent 
analogs. In each instance, the analogs with urea linkers were 
slightly more potent that the corresponding systems with 
thiourea linkers [Table 4: compare 10c-EC50 = 1.024 μM, 
10a-EC50 = 1.721 μM, 10d-EC50 = 2.814 μM, and 10b-EC50 
= 2.935 μM]. Moreover, the agents with the NO2 group [10a, 
10c] were slightly more potent than the agents with the 
CO2Et group [10b, 10d] (Table 4). The quinoline derivatives 
9a-c exhibited very weak inhibitory activity (Fig. 4) which 
indicates that a planar aryl group in that portion of the mole-
cule is ineffective compared to a flexible thiochroman unit 
present in members of 10. This is the first recorded observa-
tion of this type structure-activity analysis in heteroaroti-
noids. 
Table 4.  Potencies (EC50 values) of Growth Inhibition Activ-
ity of Cancer Versus Normal Cells 
 
Compound  A2780 Ovarian Cancer  Normal Endometrium 
10a 1.721  μM ± 0.277   2.969 μM ± 0.501 
10b 2.935  μM ± 0.163   2.666 μM ± 0.281 
10c 1.024  μM ± 0.239   2.291 μM ± 0.881 
10d 2.814  μM ± 0.425   4.536 μM ± 0.945 
 9a 4.998  μM ± 0.495  >1,000 μM 
 9b 7.861  μM ± 0.706  >1,000 μM 
 9c 4.878  μM ± 0.581  >1,000 μM 
 
 Since  10c exhibited the greatest level of activity, it is 
important to determine if it retained the differential effect on 
cancer cells over normal cells and induced apoptosis as pre-
viously observed for 10a, 10b, and 10d [17,19]. Fig. (4C) 
and Table 4 show that 10a, 10b, 10c and 10d induce differ-
ential effects on cancer cells versus normal cells demonstrat-
ing a significant therapeutic window for the compounds in 
contrast to that observed with members of 9. A short term 
increase in growth index for members of 9 and with 10a and 
10b, and to a lesser extent the tumor cells (data not in-
cluded), was not statistically significant. 
  To determine if the potent growth inhibition by 10c is 
due to induction of apoptosis, A2780 cells treated with 10 
M of the compounds for 24 hours were labeled with An-
nexin-V-FITC to detect cells undergoing apoptosis and 
propidium iodide to detect cells undergoing necrosis. Fig. (5) 
demonstrates that 10c induces positive staining for Annexin-
V-FITC in treated cells indicating that apoptosis is occur-
ring. While the majority of cells in the untreated culture   
 
 
Fig. (4). Effects of various concentrations of heteroarotinoids on 
growth of cancer and normal cells. A and B) The effect of het-
eroarotinoids on the number of living A2780 ovarian cancer cells 
were measured using the Cell Titer 96 Aqueous One Solution Cell 
Proliferation Assay. The growth index was derived by dividing the 
optical density corresponding to the number of living cells in the 
treated culture by the OD of the control cultures treated with sol-
vent only. C) The effect of 10c on retained the differential effect on 
growth inhibition of cancer versus normal cells (therapeutic win-
dow). Direct comparisons of the growth effects of 10a, 10b, 10c, 
and A2780 ovarian cancer cells and normal endometrial cells 
(Normal Endo) were compared. Heteroarotinoids with Anti-Cancer Activity Against Ovarian Cancer Cells  The Open Medicinal Chemistry Journal, 2007, Volume 1    21 
 
Fig. (5). Induction of apoptosis by 10c. Dual flow cytometric analy-
sis of Annexin-V-FITC and propidium iodide (PI) staining of 
A2780 cells grown in the absence (A) or presence (B) of 10 μM 
10c. Living cell populations are clustered in the R3 quadrant, cells 
in early apoptosis are in the R4 quadrant, and late apoptotic/necrotic 
cells are in the R2 quadrant. (C) The fold induction of apoptosis in 
cultures was derived by dividing the percentage of cells undergoing 
apoptosis in treated cultures by the number of cells undergoing 
apoptosis in untreated control cultures. 
(Fig. 5A) are located in the lower left hand quadrant corre-
sponding to negative staining for FITC and PI and indicating 
living cells, a significant proportion of the 10c treated cells 
have migrated to the lower right hand quadrant (Fig. 5B) for 
positive FITC and negative PI indicating cells undergoing 
apoptosis. Fig. (5C) compares the induction of apoptosis by 
10c with 10a in A2780 cells. Interestingly, the degree of 
apoptosis induced is slightly higher for 10c with the urea 
linker then with 10a with the thiourea linker. 
 Fig.  (4B) demonstrates that 9a has the highest efficacy 
and potency, followed by 9c then 9b  in this experiment. 
However, it is clear that members of 9 have only a small 
effect on the growth of cancerous cells and virtually no ef-
fect on the growth of normal cells. Consequently, members 
of 9 did not possess useful anti-cancer activity. 
  It is important to note that a somewhat related group of 
heteroarotinoids with semi-flexible linkers (compared to stiff 
alkenyl and alkynyl linkers between the aryl group) [6] and 
with a flexible nitrogen-containing tetrahydroquinoline unit 
and an ester linker illustrated (see below) exhibited modest 
activity in three ovarian cancer cells lines but was very ac-
tive against two cancerous vulvar cell lines [14-15]. Such 
activation by the flexible tetrahydroquinoline unit with an 
ester linker group, versus ureas or thioureas linkers as in 9 
with a planar, nitrogen-containing quinoline ring system, 
indicates that the heterocyclic ring unit should not be planar 
but should possess a flexible linker for useful activity. 
  In another example, the thiochroman-containing system 
(see below) with the amide linking group exhibited strong 
inhibition of growth of head and neck squamous cell carci-
noma (HNSCC) and induced total remission of tumor growth 
in 4 of 5 mice [48]. This compound is related to members of 
10 and supports the above hypothesis that flexible compo-
nents in the heteroarotinoid molecule are of significance in 
inducing useful biological activity. 
H
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CONCLUSIONS 
  In summary, modified heteroarotinoids were constructed 
with large hydrophobic regions in fused aryl-heterocyclic 
units. This study evaluated the relationship of structure to 
anti-cancer activity in terms of a major change in the fused, 
planar ring unit of substituted quinolines 9 as compared to 
the flexible thiochroman ring system in members of 10. This 
is an important finding to serve as a guideline for the devel-
opment of more effective heteroarotinoids. Significant toxic-
ity is not expected in these systems, given the lack of toxicity 22    The Open Medicinal Chemistry Journal, 2007, Volume 1  Le et al. 
noted with related agents in animal models of cancer [17], 
skin irritancy [17], and teratogenicity [49]. Preliminary evi-
dence suggests that 10a can be achieved and maintained in 
micromolar concentrations in animal models [50] while the 
mechanism of action to induce apoptosis occurs through di-
rect effects on mitochondria and mitochondrial proteins [25]. 
Moreover, at 3 μM the effects of 10a on differentiation has 
been observed by a normalization of the cancerous cell phe-
notype and induction of orderly tissue architecture [16]. 
  A range of activities were displayed with all compounds 
10 exhibiting inhibition of growth of malignant A2780 ovar-
ian cancer cells with EC50 values at micromolar concentra-
tions. Indeed, a good therapeutic window exists between the 
inhibitory prowess of these agents with the cancer cells ver-
sus normal D1 endometrial cells. The data establish that a 
flexible, thiochroman ring is able to induce apoptosis to a 
much greater extent than when a planar quinoline unit is pre-
sent in the heteroarotinoid molecules. Moreover, the or-
thogonal arrangement of the lone aryl ring in 10c may be 
important for induction of apoptosis. Consequently, these 
small structural changes confirm the subtle characteristics 
associated in the structure-activity relationships (SAR) of 
these heteroarotinoids with the A2780 ovarian cancer cell 
line. Agent 10c exhibited increased activity, compared to our 
current lead compound, 10a, and appears to work through a 
similar mechanism of action through induction of apoptosis, 
while retaining a therapeutic window between cancer and 
normal cells. 
  A structural investigation of the most active agents 10a, 
10c, and 10d using NMR analysis revealed very small 
changes in selected chemical shifts and in 
3JHa-Hb couplings 
over a wide temperature range. These observations indicate 
the presence of a single conformation for each compound. In 
addition, an X-ray determination of a single crystal of 10c 
demonstrated the existence of a unique lattice network in-
volving hydrogen bonding between hydrogens on N and an 
oxygen of the C=O group in a separate molecule in a stacked 
arrangement (Fig. 3). This situation did not persist in 10a 
(Fig. 3), possibly due to a lack of H-bonding between the 
hydrogens on N with the S atom in separate molecules. An-
other feature in the stacked units of 10c was the alternating 
positions of the lone phenyl ring above the fused ring unit in 
individual molecules. 
  Since it is known that 10a binds strongly to proteins in 
mouse plasma [50], it is possible that 10c binds to plasma 
proteins more efficiently than does 10a because of the strong 
H-bonding capability of 10c over 10a [presence of C=O ver-
sus C=S, respectively]. In turn, this could lead to improved 
binding to potential protein targets by 10c and therefore po-
tentially enhance efficacy in treating malignant cells. Sup-
port for this position is shown in the X-ray analysis which 
revealed stabilizing intramolecular H-bonding involving the 
oxygen atom of the carbonyl group in 10c in contrast to that 
present in 10a. Moreover, the NMR data strongly suggested 
the presence of one conformer for 10c which is likely due to 
H-bonding. Compared to the flexible thiochroman unit in 
members of 10, the planar quinoline unit in members of 9 
was a poor inducer of apoptosis and did not inhibit to any 
appreciable extent the growth of A2780 ovarian cancer cells. 
In terms of ability to inhibit cell growth or induce apoptosis, 
these observations are the first in which a heteroarotinoid 
system with a flexible, fused ring unit, a flexible linker be-
tween aryl groups, and a stabilizing linker have been evalu-
ated with a counter system possessing an aryl unit in a near 
identical type of molecule. These results will guide construc-
tion of future heteroarotinoids for improved activity. 
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